5th Circ. Continues Trend Against 'Innovator Liability'
Law360, New York (June 16, 2014, 11:43 AM EDT) -- The Fifth Circuit recently affirmed the dismissal of various claims against manufacturers of the branded drug Reglan and its generic alternative. In Eckhardt v. Qualitest Pharmaceuticals Inc., a three-judge panel joined the growing majority of courts that have rejected theories of “innovator liability” asserted against manufacturers of branded drugs. Following the U.S. Supreme Court precedent in PLIVA v. Mensing, the panel also held that claims against generic drug manufacturers sounding in product liability and breach of warranty were preempted by federal law. The panel appeared, however, to indicate that a viable parallel claim may exist where a generic manufacturer failed to...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!